Natera

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Natera reports robust Q4 results, eyes growth in genetic testing

Natera's Q4 2022 performance reflects strong growth in tests and revenues, particularly in oncology, setting the stage for future success.
The company's strategic milestones, new board appointment, and focus on clinical business growth highlight its resilience and market leadership.
While facing challenges in cost management and market competition, Natera has opportunities to leverage positive industry trends and policy changes for sustained growth.

Natera posts strong Q1 results, focuses on clinical differentiation

Natera's Q1 earnings call highlighted robust financials, strategic focus on clinical differentiation, and efforts to improve margins through ASP and COGS projects. Despite challenges with ASP and gross margins, the company remains optimistic about its trajectory and growth opportunities in women's health and organ health.

Natera reports stellar Q2 results, eyes growth amid regulatory changes

Natera delivered a strong Q2 performance with robust revenue growth, improved margins, and strategic advancements across oncology, women's health, and organ health segments.
The company showcased strengths in clinical utility, peer-reviewed publications, and litigation victories, while also addressing challenges like pricing pressures and regulatory changes.
Opportunities lie in expanding market reach through ACOG meetings, commercial coverage enhancements, and leveraging competitor exits for growth in carrier testing business.
Overall, Natera's revised guidance, financial outperformance, and focus on innovation position the company for continued success and market leadership in the genomics space.

Natera (NTRA) reports robust Q3 earnings, eyes market expansion

Natera (NTRA) delivered strong financial performance in Q3 2023, with raised revenue guidance and improved cash burn guidance.
The company's focus on achieving cash flow breakeven in 2024 while driving innovation and market engagement highlights a strategic growth trajectory.
While facing challenges such as pending lawsuits and regulatory uncertainties, Natera is well-positioned to capitalize on opportunities like market expansion and product innovation.

Natera reports robust earnings, eyes growth through strategic acquisitions

Natera's strong financial performance, strategic acquisitions, and focus on key developments position the company for continued growth.
While challenges like maintaining ASP trends and managing competition exist, opportunities in revenue growth, clinical studies, and guideline expansions offer potential upside.
Careful execution, volume growth, and momentum will be crucial for Natera's success in 2024, supported by confidence in their guidelines and innovative testing approaches.

Natera excels in Q1, eyes revenue growth and margin improvement

Natera's Q1 performance was outstanding, marked by revenue growth, margin expansion, and progress in key clinical areas.
While challenges like replicating exceptional performance and seasonal dips exist, the company is well-positioned for future growth.
Opportunities lie in improving margins, volume growth, and market penetration, supporting Natera's ambitious revenue targets.

Natera reports record-breaking Q3 earnings, poised for continued growth

Natera's Q3 2024 showcased exceptional financial performance, strong clinical advancements, and strategic debt management, positioning the company for sustained growth and innovation.
While facing challenges in community penetration and operational expenses, Natera's focus on innovation, customer service, and expanding clinical trials presents significant opportunities for future success.
With a clear focus on oncology patients, groundbreaking research, and upcoming data readouts, Natera remains poised for continued growth and leadership in the precision medicine space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

RenaCARE study expected to be fully enrolled by end of Q2 of 2022 AUSTIN, Texas , April 26, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the RenaCARE (Renasight Clinical Application, Review and Evaluation) study - a real world, prospective, multi-center clinical study to assess the clinical utility of the Renasight™ genetic testing panel. The study has already enrolled 1,600 patients across 25 sites, representing leading academic and private nephrology clinics in the U.S., and will enroll up to 2,000 patients.

Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)

AUSTIN, Texas , April 19, 2022  /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced the results of a large, real-world study1 demonstrating a high yield rate for positive genetic findings with its Renasight™ test in patients with chronic kidney disease (CKD). The  study , published in the American Journal of Nephrology, reports on renal genetic testing results using Renasight to test for 382 genes associated with CKD on 1,007 unique patient samples that were ordered by general and transplant nephrologists for clinical purposes.

Large Real-World Study with Renasight Genetic Test Highlights High Diagnostic Yield for Patients with Chronic Kidney Disease

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Natera To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 18, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA).If you suffered losses exceeding $50,000 investing in Natera stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/NTRA.

Natera Investor Alert

DEDUCE study demonstrates AUC of 0.86 in overall cohort, including more than 700 prospective samples AUSTIN, Texas , April 13, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its clinical validation study1 on its donor-derived cell-free DNA (dd-cfDNA) test for the assessment of acute rejection in heart transplant patients, Prospera™ Heart, has been published in the Journal of Heart and Lung Transplantation - a leading journal with the highest impact factor in the transplantation sector2. This multi-site clinical validation, named the DEDUCE study, was conducted in partnership with the University of Utah and the University of California, San Diego and evaluated 703 prospective and 108 retrospective samples, (811 samples total) from 223 patients.

Multi-Site Clinical Validation of Prospera Heart Test Demonstrates Outstanding Performance in Assessing Heart Transplant Rejection

Signatera ctDNA dynamics are both predictive and prognostic in neoadjuvant TNBC. Lead time up to 30 months between Signatera positivity and radiographic recurrence.

Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting

San Francisco, California--(Newsfile Corp. - April 7, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses to submit your losses now. The firm is investigating possible violations of the securities laws.Visit: www.hbsslaw.com/investor-fraud/NTRAContact An Attorney Now: NTRA@hbsslaw.com844-916-0895Natera, Inc. (NASDAQ: NTRA) Investigation:The investigation concerns the propriety of Natera's billing practices for its DNA screening tests.On Mar. 9, 2022, questions about Natera's billing practices came t

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Natera, Inc. (NTRA) For Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm's Attorneys

AUSTIN, Texas , April 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of the VALID study 1, showcasing its Prospera™ Lung donor-derived cell-free DNA (dd-cfDNA) test in assessing rejection and allograft injury in lung transplant patients. The blinded prospective clinical validation, published in Transplant Direct, analyzed 195 biopsy-matched samples from 103 patients with cohort demographics that closely mirrored those reported to the Scientific Registry of Transplant Recipients (SRTR).

Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment Test

New York, New York--(Newsfile Corp. - April 6, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA) resulting from allegations that Natera may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Natera securities you may be entitled to compensation without payment of any out of pocket fees or costs through...

NTRA LOSS ALERT: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Natera, Inc. Investors with Losses to Inquire About Class Action Investigation - NTRA

Sangeeta Bhorade, M.D., appointed as head of organ health medical affairs AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the hiring of Sangeeta Bhorade, M.D.

Natera Adds to Organ Health Medical Affairs Leadership Team

AUSTIN, Texas , April 1, 2022 /PRNewswire/ -- Natera , Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced the results of a study1 to examine both total and donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients hospitalized with COVID-19 using its Prospera™ test to assess disease severity and risk of rejection. The study , published in Transplantation Proceedings, used the Prospera test to examine the relationship between total cfDNA and dd-cfDNA fraction when monitoring for rejection.

Natera Announces Publication Highlighting Importance of Testing Total cfDNA when Monitoring Kidney Transplant Patients with COVID-19 Infection

Boston, Massachusetts--(Newsfile Corp. - March 31, 2022) - Block & Leviton is investigating Natera, Inc. (NASDAQ: NTRA) for potential securities law violations. Investors who have lost money in their Natera, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ntra.What is this all about?On March 9, 2022, before the market opened, Hindenburg Research issued a short report alleging that "Natera's revenue growth has been...

Natera, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Company recognized for its ability to monitor therapy response with its Signatera™ MRD test AUSTIN, Texas , March 28, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, has been named to Fast Company's annual list of the  World's Most Innovative Companies  for 2022. Natera ranked sixth in the  Health  category and was recognized for its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its ability to monitor immunotherapy response.

Natera Listed as One of World's Most Innovative Health Companies by Fast Company

San Francisco, California--(Newsfile Corp. - March 23, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses to submit your losses now. The firm is investigating possible violations of the securities laws.Visit: www.hbsslaw.com/investor-fraud/NTRAContact An Attorney Now: NTRA@hbsslaw.com844-916-0895Natera, Inc. (NASDAQ: NTRA) Investigation:The investigation concerns the propriety of Natera's billing practices for its DNA screening tests.On Mar. 9, 2022, questions about Natera's billing practices came

NTRA INVESTIGATION: Hagens Berman, National Trial Attorneys, Investigating Natera, Inc. (NTRA) For Possible Securities Law Violations, Investors With Significant Losses Encouraged to Contact Firm

Atara Biotherapeutics

Travere Therapeutics

HAYWARD, Calif.--(BUSINESS WIRE)-- #Biotech--Dr. Roy D. Baynes has been appointed Executive Vice President and Chief Medical Officer of Eikon Therapeutics effective July 11, 2022.

Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

Biopsy-matched study assesses pancreas rejection in the context of a simultaneous kidney-pancreas transplant AUSTIN, Texas , March 22, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a study1 reporting on the performance of donor-derived cell-free DNA (dd-cfDNA) testing using the Prospera™ technology for the assessment of pancreas graft rejection in simultaneous pancreas-kidney (SPK) transplantation has been published in Transplantation, the official Journal of The Transplantation Society . The study, conducted at the Hospital Clinic of Barcelona, Spain, utilized Prospera technology to detect rejection of a pancreas graft in 36 SPK transplant recipients with pancreas biopsy-matched plasma samples.

New Data in Simultaneous Pancreas-Kidney Transplantation Further Demonstrates the Value of Prospera dd-cfDNA Technology

Updated analysis shows 75% detection of recurrence with a single blood draw 4 weeks post surgery AUSTIN, Texas, March 21, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new Signatera data from the prospective, multi-center CIRCULATE-Japan trial, presented by Dr. Eiji Oki of Kyushu University in an oral presentation at the Society of Surgical Oncology (SSO) 2022 International Conference on Surgical Cancer Care. CIRCULATE-Japan is the largest molecular residual disease (MRD)-guided clinical trial with more than 3,300 stage I-IV colorectal cancer (CRC) patients enrolled to date.

Natera Announces Updated Signatera™ MRD Data from CIRCULATE-Japan Presented in Plenary Talk at the Society of Surgical Oncology Conference, and Activation of CIRCULATE-US Trial

ALSP Orchid Acquisition Corp I

Bumble

Although US stock futures traded lower this morning on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain.

Insiders Buy Over $15M Of 3 Stocks

The report claims the company's billing practices are deceptive.

Should You Buy Natera Stock Despite the Scathing Short-Seller Report From Hindenburg?

San Francisco, California--(Newsfile Corp. - March 17, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses to submit your losses now. The firm is investigating possible violations of the securities laws.Visit: www.hbsslaw.com/investor-fraud/NTRAContact An Attorney Now: NTRA@hbsslaw.com844-916-0895Natera, Inc. (NASDAQ: NTRA) Investigation:The investigation concerns the propriety of Natera's billing practices for its DNA screening tests.On Mar. 9, 2022, questions about Natera's billing practices came

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Natera, Inc. (NTRA) For Possible Securities Law Violations, Investors With Significant Losses Encouraged to Contact Firm

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, announces that it is investigating potential violations of the federal securities laws by Natera Inc. (NASDAQ:NTRA). On March 9, 2022, before the market opened, Hindenburg Research issued a short report alleging that "Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers." The report includes other

SHAREHOLDER ALERT - Labaton Sucharow Investigating Natera Inc. - NTRA

AUSTIN, Texas, March 16, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that Roelof Botha, lead independent director of Natera's board of directors and partner at Sequoia Capital, has invested $5 million to purchase shares of Natera's stock on the open market. "I have strong confidence in Natera's business and in its strategic and commercial execution capabilities," said Mr.

Roelof Botha, Lead Independent Director of Natera Board, Makes $5 Million Investment in Natera

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Natera investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact inf

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Natera, Inc. (NTRA) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) investors concerning the Company's possible violations of the federal securities laws. On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, alleging that positive results on tests are incorrect approximately 85 percent of the time, and that patients who receive a positive res

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Natera, Inc. (NTRA) on Behalf of Investors

AUSTIN, Texas, March 15, 2022 /PRNewswire/ -- A jury in Delaware District Court found that both CareDx, Inc. and Natera, Inc. engaged in false advertising – including that CareDx made materially false statements about its involvement in and funding of a scientific publication. Specifically, the evidence showed that CareDx senior leadership misled investors and physicians regarding CareDx's drafting and funding of a paper that they claimed was independent, when it was not.

Jury Finds CareDx and Natera Engaged in False Advertising

Leadership, Board to Exchange Cash Compensation for Shares  AUSTIN, Texas, March 14, 2022 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that its executive leaders and board of directors have unanimously agreed on a compensation change that will see them take company stock instead of their salaries and retainers for the remainder of 2022.  Steve Chapman, CEO, Mike Brophy, CFO, Bob Schueren, COO, Jonathan Sheena, co-founder and director, and Matthew Rabinowitz, executive chairman, along with all of Natera's non-employee directors, will be taking their salaries and retainers in equity for the remainder of 2022.

News for Natera Stock (NTRA)